Allarity Therapeutics Provides Update on Dovitinib Program FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...

Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress - Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib - Poster provides new details of the DRP® companion diagnostic for dovitinib,...

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma - Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Press release   Hørsholm, Denmark (9 March 2021) – Allarity...

Allarity Therapeutics Provides Update on Dovitinib Program Press release       Hørsholm, Denmark (23 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced several updates related to its planned filing of a new drug...